Diabetes mellitus type 2 (T2D) as a comorbidity of Chronic Obstructive Pulmonary Disease (COPD)
Date Issued
2022-01
Author(s)
Mickovski Ivana
Abstract
We aimed to investigate the
association between COPD and T2D
and the relation to the severity of
airflow limitation.
Cross-sectional study including 120
patients with initially diagnosed COPD,
aged 40 to 75 years and 60 nonCOPD subjects matched by age,
smoking status, body mass index, as
controls. All study participants
underwent anthropometric
measurements, fasting blood sugar
(FBS), oral glucose tolerance test
(OGTT) (performed in patients with
fasting blood sugar level 5.6-
6.1mmol/L (measured two times), lipid
profile, CRP, pulmonary evaluation
(dyspnea severity assessment,
baseline and post-bronchodilator
spirometry, gas analyses, chest X-ray).
Results presented statistically
significant difference in presence of
T2D in COPD patients compared to
controls (45.0% vs 20.0%; P=0.0011).
According to the GOLD classification,
the frequencies of T2D in COPD
patients were categorized in stages I,
II, III, IV (25.0%, 43.3%, 52.5%,
58.3%, respectively), and according to
combined assessment test in A, B, C,
D (29.2%, 37.5%, 35.0%, 41.7%
respectively). In GOLD 2 stage the risk
for T2D was 2.3 times higher than
GOLD1. COPD patients with T2D
presented significant association with
pulmonary function. FBS was higher in
COPD than controls (8.4±1.1mmol/L
vs 4.9±2.1mmol/L) with statistical
significance (p<0.0001), but HDL was
lower in COPD than controls
(39.1±6.4mg/dl vs 49.6±3.9mg/dl) with
statistical significance (p<0.0001).We found higher prevalence of T2D in
patients with COPD even in early
COPD stages compared to nonCOPD. Our findings suggest
multidisciplinary approach in COPD
patients for prevention, diagnosis and
early start of treatment.
association between COPD and T2D
and the relation to the severity of
airflow limitation.
Cross-sectional study including 120
patients with initially diagnosed COPD,
aged 40 to 75 years and 60 nonCOPD subjects matched by age,
smoking status, body mass index, as
controls. All study participants
underwent anthropometric
measurements, fasting blood sugar
(FBS), oral glucose tolerance test
(OGTT) (performed in patients with
fasting blood sugar level 5.6-
6.1mmol/L (measured two times), lipid
profile, CRP, pulmonary evaluation
(dyspnea severity assessment,
baseline and post-bronchodilator
spirometry, gas analyses, chest X-ray).
Results presented statistically
significant difference in presence of
T2D in COPD patients compared to
controls (45.0% vs 20.0%; P=0.0011).
According to the GOLD classification,
the frequencies of T2D in COPD
patients were categorized in stages I,
II, III, IV (25.0%, 43.3%, 52.5%,
58.3%, respectively), and according to
combined assessment test in A, B, C,
D (29.2%, 37.5%, 35.0%, 41.7%
respectively). In GOLD 2 stage the risk
for T2D was 2.3 times higher than
GOLD1. COPD patients with T2D
presented significant association with
pulmonary function. FBS was higher in
COPD than controls (8.4±1.1mmol/L
vs 4.9±2.1mmol/L) with statistical
significance (p<0.0001), but HDL was
lower in COPD than controls
(39.1±6.4mg/dl vs 49.6±3.9mg/dl) with
statistical significance (p<0.0001).We found higher prevalence of T2D in
patients with COPD even in early
COPD stages compared to nonCOPD. Our findings suggest
multidisciplinary approach in COPD
patients for prevention, diagnosis and
early start of treatment.
File(s)![Thumbnail Image]()
Loading...
Name
MILANOABSTRACT-BOOK_draft_2022.01.13.pdf
Size
913.31 KB
Format
Adobe PDF
Checksum
(MD5):fb0c09cb76e9bbf1676d9d0d8fb7293a